ZYXI vs ABT

For growth investors, Abbott Laboratories (ABT) is the stronger pick with 4.

6% revenue growth year-over-year, versus 4. 4% for Zynex, Inc. (ZYXI). Zynex, Inc. (ZYXI) offers the better valuation at 0. 6x trailing P/E, making it the more compelling value choice. Analysts rate Abbott Laboratories (ABT) a "Buy" — based on 41 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Zynex, Inc.

(ZYXI) is the cheapest at 0. 6x versus Abbott Laboratories at 11. 4x.

Over the past 5 years, Abbott Laboratories (ABT) delivered a total return of -17.

9%, compared to -98. 9% for Zynex, Inc. (ZYXI). Over 10 years, the gap is even starker: ABT returned +173. 7% versus ZYXI's -29. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Abbott Laboratories (ABT) is the lower-risk stock at 0.

25β versus Zynex, Inc. 's 4. 55β — meaning ZYXI is approximately 1732% more volatile than ABT relative to the S&P 500. On balance sheet safety, Abbott Laboratories (ABT) carries a lower debt/equity ratio of 32% versus 2% for Zynex, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Abbott Laboratories (ABT) is pulling ahead at 4.

6% versus 4. 4% for Zynex, Inc. (ZYXI). On earnings-per-share growth, the picture is similar: Abbott Laboratories grew EPS 133. 6% year-over-year, compared to -66. 7% for Zynex, Inc.. Over a 3-year CAGR, ZYXI leads at 13. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Abbott Laboratories (ABT) is the more profitable company, earning 31.

9% net margin versus 1. 6% for Zynex, Inc. — meaning it keeps 31. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABT leads at 16. 3% versus 3. 1% for ZYXI. At the gross margin level — before operating expenses — ZYXI leads at 79. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

All stocks in this comparison pay dividends.

Abbott Laboratories (ABT) offers the highest yield at 2. 5%, versus 0. 5% for Zynex, Inc. (ZYXI).

For long-horizon retirement investors, Abbott Laboratories (ABT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

25), 2. 5% yield, +173. 7% 10Y return). Zynex, Inc. (ZYXI) carries a higher beta of 4. 55 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABT: +173. 7%, ZYXI: -29. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.